Provided by Tiger Trade Technology Pte. Ltd.

Glaukos

109.60
+4.374.15%
Post-market: 109.600.00000.00%19:01 EDT
Volume:706.19K
Turnover:76.51M
Market Cap:6.37B
PE:-33.40
High:109.67
Open:106.46
Low:105.40
Close:105.23
52wk High:130.23
52wk Low:73.16
Shares:58.08M
Float Shares:55.40M
Volume Ratio:0.85
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2819
EPS(LYR):-3.2819
ROE:-26.38%
ROA:-5.80%
PB:9.70
PE(LYR):-33.40

Loading ...

Closing Bell Movers: Glaukos slips 13% after pre-announcement

TIPRANKS
·
Jan 14

Glaukos Shares Slide After 4Q Sales Forecast for iDose Implant Disappoints

Dow Jones
·
Jan 14

Glaukos: Solid Fundamentals, Strong Multi-Segment Growth, and iDose Trajectory Support a Buy Rating Despite Near-Term Volatility

TIPRANKS
·
Jan 14

Glaukos Reports Strong Preliminary Q4 and 2025 Sales Growth

TIPRANKS
·
Jan 14

Glaukos Reaffirms 2026 Revenue Guidance of $600 Million to $620 Million, Shares Fall After Hours

MT Newswires Live
·
Jan 14

Glaukos Unveils Investor Presentation Highlighting Innovation in Eye Disease Treatments

Reuters
·
Jan 14

BRIEF-Glaukos Announces Preliminary, Unaudited Fourth Quarter Results

Reuters
·
Jan 14

Glaukos' Q4 preliminary sales rise 36%, beat estimates

Reuters
·
Jan 14

Glaukos sees Q4 revenue about $143M, consensus $129.46M

TIPRANKS
·
Jan 14

Glaukos raises FY25 revenue view to roughly $507M from $490M-$495M

TIPRANKS
·
Jan 14

BRIEF-Glaukos Q4 Sales USD 143 Million Vs. IBES Estimate USD 131.2 Million

Reuters
·
Jan 14

Glaukos Q4 Sales USD 143 Million VS. Ibes Estimate USD 131.2 Million

THOMSON REUTERS
·
Jan 14

Glaukos Outlook FY Sales USD 600-620 Million

THOMSON REUTERS
·
Jan 14

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

THOMSON REUTERS
·
Jan 14

Glaukos price target raised to $138 from $112 at Goldman Sachs

TIPRANKS
·
Jan 09

Glaukos (GKOS) Gets a Buy from Piper Sandler

TIPRANKS
·
Jan 08

Glaukos Price Target Maintained With a $116.00/Share by BTIG

Dow Jones
·
Jan 02

S&P 500 Futures Flat In Premarket Trading; United Therapeutics, Intel Lag

Dow Jones
·
Dec 24, 2025

Glaukos Is Maintained at Buy by UBS

Dow Jones
·
Dec 23, 2025

Truist Securities Adjusts Price Target on Glaukos Corp to $145 From $120, Maintains Buy Rating

MT Newswires Live
·
Dec 18, 2025